COMMUNIQUÉS West-GlobeNewswire

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
30/10/2024
WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for WVE-007 demonstrate opportunities for monotherapy, for synergistic use with GLP-1s, and for [...]
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
30/10/2024
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug [...]
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
30/10/2024
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
Cellectis publiera ses résultats financiers du troisième trimestre 2024 le 4 novembre 2024
30/10/2024
NEW YORK, 30 oct. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer [...]
STERIS Declares Dividend of $0.57 per share
30/10/2024
DUBLIN, IRELAND, Oct. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is [...]
VitalHub Announces Acquisition of Strata Health
30/10/2024
TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has acquired (the “Acquisition”) Strata Health Solutions Inc. (“Strata [...]
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
30/10/2024
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis resulted in a 7.7-fold [...]
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
30/10/2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after market close on Wednesday [...]
Prenetics Announces Participation in the Sidoti Virtual Micro Cap Investor Conference
30/10/2024
CHARLOTTE, N.C., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Prenetics, (NASDAQ: PRE) a leading health sciences company, announced today that management will participate in the Sidoti Virtual Micro Cap Conference being held on [...]
TOMI Environmental Solutions, Inc. Reports Consecutive Quarterly Net Profit
30/10/2024
- Company Reports Operating Income of $149,000 and Positive Net Income - Performance Driven by Growth in International, Mobile Equipment, and iHP Corporate Service Sales FREDERICK, Md., Oct. 30, 2024 (GLOBE NEWSWIRE [...]
Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
30/10/2024
First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri’s ability to deliver more SN-38 to tumors compared with either irinotecan or [...]
Teladoc Health Reports Third Quarter 2024 Results
30/10/2024
PURCHASE, NY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended September 30, 2024 (“Third [...]
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
30/10/2024
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
30/10/2024
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced [...]
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
30/10/2024
AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the [...]
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
30/10/2024
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), Aligos a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class [...]
Cytek Biosciences to Participate in Upcoming Investor Conferences
30/10/2024
FREMONT, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor [...]
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
30/10/2024
-- Strong Cash Position of $306 Million; 9 th Consecutive Quarter of Positive or Neutral Cash Balance -- -- Total Net Revenue of $42 Million Represents Continued Source of Cash from the U.S., RoW Partnerships and Early [...]
Merit Medical Reports Third Quarter 2024 Results and Raises Full-Year Guidance
30/10/2024
Third Quarter 2024 Highlights† Reported revenue of $339.8 million, up 7.8% Constant currency revenue* and constant currency revenue, organic* up 7.9% and up 5.7%, respectively GAAP operating margin of 11.0%, compared to [...]

Pages